NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Secures Market Entry for Yesintek™, a Proposed Biosimilar to Stelara®, in Additional Global Markets

Bengaluru, Karnataka, India, October 26, 2026

Biocon Limited (BSE code: 532523, NSE: BIOCON) has signed a license agreement with Janssen Sciences Ireland clearing the way for the commercialization of Yesintek™, its proposed biosimilar to Stelara® (Ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect.

This milestone builds on the Company's previously announced agreements with Janssen that secured market entry dates for Yesintek™ in the United States, and in Europe, the UK, Canada and Japan.

These additional market entry rights for biosimilar Ustekinumab will allow Biocon to offer an affordable and effective treatment option for patients impacted by autoimmune diseases in these markets.

Yesintek™ is a human interleukin-12 and -23 antagonist that disrupts IL-12 and IL-23 mediated signalling in immune mediated diseases and has been approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The reference brand, Stelara®, had worldwide sales of $6.08 billion in 2025^.

^Johnson & Johnson Reported 2025 Sales

Note:

- *All trademarks, registered or unregistered, are the property of their respective owners.*
- *Product launches in all the countries / regions are subject to regulatory approval.*

Forward-Looking Statement: *Statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update these statements except as required by law.*